Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin

Science. 1998 Oct 16;282(5388):490-3. doi: 10.1126/science.282.5388.490.

Abstract

Toxic epidermal necrolysis (TEN, Lyell's syndrome) is a severe adverse drug reaction in which keratinocytes die and large sections of epidermis separate from the dermis. Keratinocytes normally express the death receptor Fas (CD95); those from TEN patients were found to express lytically active Fas ligand (FasL). Antibodies present in pooled human intravenous immunoglobulins (IVIG) blocked Fas-mediated keratinocyte death in vitro. In a pilot study, 10 consecutive individuals with clinically and histologically confirmed TEN were treated with IVIG; disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIG may be an effective treatment.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Blocking / immunology
  • Antibodies, Blocking / therapeutic use
  • Apoptosis*
  • Child
  • Dermis / pathology
  • Disease Progression
  • Epidermis / pathology
  • Fas Ligand Protein
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Jurkat Cells
  • Keratinocytes / metabolism
  • Keratinocytes / pathology*
  • Male
  • Membrane Glycoproteins / metabolism
  • Middle Aged
  • Pilot Projects
  • Stevens-Johnson Syndrome / pathology
  • Stevens-Johnson Syndrome / therapy*
  • fas Receptor / immunology
  • fas Receptor / physiology*

Substances

  • Antibodies, Blocking
  • FASLG protein, human
  • Fas Ligand Protein
  • Immunoglobulins, Intravenous
  • Membrane Glycoproteins
  • fas Receptor